Amneal Pharmaceuticals has received approval from the Food and Drug Administration for a dementia treatment and a drug targeting certain types of brain tumors, as well as tentative approval for a drug ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
University Hospitals Brain Health & Memory Center is now treating patients with KISUNLAâ„¢ (donanemab), a Food and Drug ...
In today’s fast-paced world, maintaining optimal cognitive function is essential. Many people struggle with brain fog, ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The FDA is set to consider approval of an alternative to ... which act directly on the brain and can lead to addiction. The drug has been billed as nonaddictive by Vertex, though some experts ...
The long quest for powerful non-opioid drugs that treat pain without risk of addiction is nearing a milestone, in the form of a pill that could soon win approval from the Food and Drug Administration.
GlobalData on MSN9d
Eisai and Biogen’s subcutaneous Leqembi set for FDA reviewEisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment ...
People who are newly diagnosed with Alzheimer’s and their caregivers need more support in navigating the healthcare system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback